Last update Feb. 10, 2019

Pipemidic Acid

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Antibiotic of the quinolone type, active in vitro against Pseudomonas aeruginosa, structurally related to nalidixic acid.
It has been used orally and intravenously (two daily doses) to treat urinary tract infections from Gram-negative bacteria (Shimizu M 1975).

SInce the last update we have not found published data on its excretion in breastmilk.

Low toxicity in humans has been reported (Azierta 2016).

This product has very few bibliographical references.

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity or glucose-6-phosphate dehydrogenase deficiency.

The possible negativity of cultures in febrile infants whose mothers take antibiotics should be taken into account, as well as the possibility of gastroenteritis due to alteration of the intestinal flora (Ito 1993).


See below the information of this related product:

  • Nalidixic Acid (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)

Alternatives

  • Ciprofloxacin ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Norfloxacin ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ofloxacin ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Pipemidic Acid is also known as


Pipemidic Acid in other languages or writings:

Group

Pipemidic Acid belongs to this group or family:

Tradenames

Main tradenames from several countries containing Pipemidic Acid in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 93 %
Molecular weight 303 daltons
Protein Binding 39 %
VD 1.7 l/Kg
Tmax 1.1 hours
T½ 3.5 hours

References

  1. Azierta. Pipemidic acid. Drug Summary. 2016 Full text (in our servers)
  2. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  3. Klinge E, Männistö PT, Mäntylä R, Mattila J, Hänninen U. Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers. Antimicrob Agents Chemother. 1984 Abstract
  4. Shimizu M, Nakamura S, Takase Y, Kurobe N. Pipemidic acid: absorption, distribution, and excretion. Antimicrob Agents Chemother. 1975 Abstract
  5. Shimizu M, Takase Y, Nakamura S, Katae H, Minami A. Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties. Antimicrob Agents Chemother. 1975 Abstract

Total visits

8,484

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM